Skip to main content
. Author manuscript; available in PMC: 2019 Apr 19.
Published in final edited form as: Cell. 2018 Apr 19;173(3):649–664.e20. doi: 10.1016/j.cell.2018.03.052

Figure 6. GAS6-AS2 Activates GAS6/TAM Signaling.

Figure 6

(A) Pearson correlation between GAS6-AS2 and GAS6 expression levels following GAS6- AS2 activation. Data are represented as mean of triplicate measurements.

(B) Pearson correlation between GAS6-AS2 and GAS6 expression levels across the 760 cancer cell lines analyzed (Figure 1A-B).

(C) Pearson correlation between GAS6-AS2 and GAS6 expression levels in AML patient samples.

(D) Western blot analysis of differential GAS6/TAM signaling activation in response to individual control or GAS6-AS2 sgRNA overexpression.

(E) Pearson correlation between GAS6-AS2 and AXL expression levels in AML patient samples.

(F) Pearson correlation between GAS6-AS2 and AXL expression levels across the 760 cancer cell lines analyzed (Figure 1A-B).

(G) Expression levels of GAS6-AS2, GAS6, and AXL in MOLM14 and K562 cell lines.

(H) Ara-C efficacy measurements in MOLM14 and K562 cell lines, based on normalized MTS reads following 48 hours of treatment with the indicated concentrations of Ara-C. Data are represented as mean ± SD, n = 3.